Recombinant Human Siglec-2/CD22 (C-His)
Shipping Info:
For estimated delivery dates, please contact us at [email protected]
| Amount : | 50 µg |
| Content : | Lyophilized from a 0.2 um filtered solution of PBS, pH 7.4 |
| AA sequence : | Recombinant Human Siglec-2 is produced by Human 293 Cells. The target gene encoding D20-R687 is expressed with a 10His tag at the C-terminus. |
| Alternative Name : | CD22, SIGLEC2, BL-CAM, SIGLEC-2, Siglec2, SIGLEC2FLJ22814 |
Source : Human 293 Cells;
B-cell receptor CD22, also known as Siglec-2, is a member of the immunoglobulin superfamily, SIGLEC family of lectins. CD22 is expressed by B-lymphocytes and can mediate B-cell B-cell interactions, as well as the localization of B-cells in lymphoid tissues. CD22 binds sialylated glycoproteins, one of which is CD45. As an inhibitory coreceptor of the B-cell receptor (BCR), CD22 plays a central role in establishing signaling thresholds for B-cell activation. CD19 regulates CD22 phosphorylation by augmenting Lyn kinase activity, while CD22 inhibits CD19 phosphorylation via SHP-1.
B-cell receptor CD22, also known as Siglec-2, is a member of the immunoglobulin superfamily, SIGLEC family of lectins. CD22 is expressed by B-lymphocytes and can mediate B-cell B-cell interactions, as well as the localization of B-cells in lymphoid tissues. CD22 binds sialylated glycoproteins, one of which is CD45. As an inhibitory coreceptor of the B-cell receptor (BCR), CD22 plays a central role in establishing signaling thresholds for B-cell activation. CD19 regulates CD22 phosphorylation by augmenting Lyn kinase activity, while CD22 inhibits CD19 phosphorylation via SHP-1.
|
There are currently no product reviews
|
.png "ACE2/HEK293 Stable Cell Line")
